HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Nilsen, E. V. Articles by Fotis, M. A. Search for Related Content PubMed PubMed Citation Articles by Nilsen, E. V. Articles by Fotis, M. A.

EGIL V. NILSEN, M.S., is Director, Operations and Quality Improvement, Department of Performance Management, Westchester Medical Center, Valhalla Campus, Valhalla, NY; at the time of the study he was Managing Consultant, Navigant Consulting, Inc., Chicago, IL. MICHAEL A. FOTIS, B.S.PHARM., is Director, Pharmacy Practice Residency, and Manager, Drug Information Center, Northwestern Memorial Hospital, Chicago.

Address correspondence to Mr. Nilsen at TCC Executive Offices, 95 Grasslands Road, Valhalla, NY 10595.

Purpose. A study was conducted to develop a model to identify adverse drug events (ADEs) and quantify their effect on quality and cost in a large tertiary care hospital. Methods. The drug–ADE relationship between unfractionated heparin and heparin-induced bleeding was studied for all inpatients receiving heparin infusions at the hospital between January 1 and December 31, 2004. Activated partial thromboplastin time (aPTT) values were used to help determine if the patients received blood products in response to excessive anticoagulation with heparin. The number of aPTT values of 150 seconds and the last aPTT value before discharge were evaluated. The key outcome measures were length of stay, cost per admission, and mortality. Of the 1455 admissions to the hospital, 122 patients received blood products before receiving heparin infusion only, 264 received blood products after receiving the drug only, 221 received blood products both before and after, and 848 who received the drug never received blood products. Results. Differences in full cost and length of stay between the group receiving heparin infusion only and the groups receiving both blood products were significant. Differences in mortality between the group only receiving heparin infusion and the groups receiving both heparin infusion and blood products were also significant. Conclusion. Using the model developed to study the effect of heparin-induced bleeding, we found that the cost per patient day was highest for patients receiving blood products after heparin infusion treatment. There was a positive correlation between one or more aPTT values of 150 seconds and undesirable patient outcomes. Index terms: Anticoagulants; Blood derivatives; Costs; Economics; Hemorrhage; Heparin; Hospitals; Methodology; Models; Mortality; Patient care; Quality assurance; Toxicity